Freeze-and-thaw-disrupted tumour cells impair the responsiveness of DC to TLR stimulation

European Journal of Immunology

Volumn 38, Issue 10, 2008, Pages 2740-2750

  Tirapu, Iñigo ^a   Lewis, Amy ^a   Kreutz, Martin ^a   McLinden, Hayley ^a   Diebold, Sandra S ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Apoptosis; Dendritic cells; Immunotherapy; Toll like receptors

Indexed keywords

PHOSPHATIDYLSERINE; TOLL LIKE RECEPTOR; TUMOR VACCINE; CD40 ANTIGEN; CD86 ANTIGEN; INTERLEUKIN 12; INTERLEUKIN 6; LIPOSOME;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL ACTIVATION; CELL DISRUPTION; CELL MEMBRANE; CONTROLLED STUDY; DENDRITIC CELL; FREEZE THAWING; IMMUNE RESPONSE; IMMUNOMODULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL; TUMOR IMMUNITY; VACCINE PRODUCTION; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; CERCOPITHECUS; DRUG EFFECT; EXPERIMENTAL MELANOMA; FREEZING; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; NEOPLASM; PHYSIOLOGY; TUMOR CELL LINE; VERO CELL;

ANIMALS; ANTIGENS, CD40; ANTIGENS, CD86; CELL LINE, TUMOR; CERCOPITHECUS AETHIOPS; DENDRITIC CELLS; FREEZING; IMMUNOTHERAPY; INTERLEUKIN-12; INTERLEUKIN-6; LIPOSOMES; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; NEOPLASMS; PHOSPHATIDYLSERINES; TOLL-LIKE RECEPTORS; VERO CELLS;

EID: 58149232492     PISSN: 00142980     EISSN: 15214141     Source Type: Journal    
DOI: 10.1002/eji.200838284     Document Type: Article

References (57)

1. Schuler, G., Schuler-Thurner, B. and Steinman, R. M., The use of dendritic cells in cancer immunotherapy. Curr. Opin. Immunol. 2003. 15: 138-147.
2. Banchereau, J. and Palucka, A. K., Dendritic cells as therapeutic vaccines against cancer. Nat. Rev. Immunol. 2005. 5: 296-306.
3. Ahmad, M., Rees, R. C. and Ali, S. A., Escape from immunotherapy: possible mechanisms that influence tumor regression/progression. Cancer Immunol. Immunother. 2004. 53: 844-854.
4. Tsushima, H., Kawata, S., Tamura, S., Ito, N., Shirai, Y., Kiso, S., Imai, Y. et al., High levels of transforming growth factor beta 1 in patients with colorectal cancer: Association with disease progression. Gastroenterology 1996. 110: 375-382.
5. Fortis, C., Foppoli, M., Gianotti, L., Galli, L., Citterio, G., Consogno, G., Gentilini, O. and Braga, M., Increased interleukin-10 serum levels in patients with solid tumours. Cancer Lett. 1996. 104: 1-5.
6. De Smedt, T., Van Mechelen, M., De Becker, G., Urbain, J., Leo, O. and Moser, M., Effect of interleukin-10 on dendritic cell maturation and function. Eur. J. Immunol. 1997. 27: 1229-1235.
7. Sharma, S., Stolina, M., Lin, Y., Gardner, B., Miller, P. W., Kronenberg, M. and Dubinett, S. M., T cell-derived IL-10 promotes lung cancer growth by suppressing both T cell and APC function. J. Immunol. 1999. 163: 5020-5028.
8. Bellone, G., Turletti, A., Artusio, E., Mareschi, K., Carbone, A., Tibaudi, D., Robecchi, A. et al., Tumor-associated transforming growth factor-beta and interleukin-10 contribute to a systemic Th2 immune phenotype in pancreatic carcinoma patients. Am. J. Pathol. 1999. 155: 537-547.
9. Nouri-Shirazi, M., Banchereau, J., Bell, D., Burkeholder, S., Kraus, E. T., Davoust, J. and Palucka, K. A., Dendritic cells capture killed tumor cells and present their antigens to elicit tumor-specific immune responses. J. Immunol. 2000. 165: 3797-3803.
10. Chang, A. E., Redman, B. G., Whitfield, J. R., Nickoloff, B. J., Braun, T. M., Lee, P. P., Geiger, J. D. and Mule, J. J., A phase I trial of tumor lysate-pulsed dendritic cells in the treatment of advanced cancer. Clin. Cancer Res. 2002. 8: 1021-1032.
11. Maier, T., Tun-Kyi, A., Tassis, A., Jungius, K. P., Burg, G., Dummer, R. and Nestle, F. O., Vaccination of patients with cutaneous T-cell lymphoma using intranodal injection of autologous tumor-lysate-pulsed dendritic cells. Blood 2003. 102: 2338-2344.
12. O'Rourke, M. G., Johnson, M., Lanagan, C., See, J., Yang, J., Bell, J. R., Slater, G. J. et al., Durable complete clinical responses in a phase I/II trial using an autologous melanoma cell/ dendritic cell vaccine. Cancer Immunol. Immunother. 2003. 52: 387-395.
13. Albert, M. L., Death-defying immunity: Do apoptotic cells influence antigen processing and presentation? Nat. Rev. Immunol. 2004. 4: 223-231.
14. Rock, K. L., Hearn, A., Chen, C. J. and Shi, Y., Natural endogenous adjuvants. Springer Semin. Immunopathol. 2005. 26: 231-246.
15. Melcher, A., Todryk, S., Hardwick, N., Ford, M., Jacobson, M. and Vile, R. G., Tumor immunogenicity is determined by the mechanism of cell death via induction of heat shock protein expression. Nat. Med. 1998. 4: 581-587.
16. Shi, Y., Evans, J. E. and Rock, K. L., Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 2003. 425: 516-521.
17. Voll, R. E., Herrmann, M., Roth, E. A., Stach, C., Kalden, J. R. and Girkontaite, I., Immunosuppressive effects of apoptotic cells. Nature 1997. 390: 350-351.
18. Melcher, A., Gough, M., Todryk, S. and Vile, R., Apoptosis or necrosis for tumor immunotherapy: What's in a name? J. Mol. Med. 1999. 77: 824-833.
19. Matzinger, P., Tolerance, danger, and the extended family. Annu. Rev. Immunol. 1994. 12: 991-1045.
20. Gallucci, S., Lolkema, M. and Matzinger, P., Natural adjuvants: endogenous activators of dendritic cells. Nat. Med. 1999. 5: 1249-1255.
21. Scaffidi, P., Misteli, T. and Bianchi, M. E., Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 2002. 418: 191-195.
22. Strome, S. E., Voss, S., Wilcox, R., Wakefield, T. L., Tamada, K., Flies, D., Chapoval, A. et al., Strategies for antigen loading of dendritic cells to enhance the antitumor immune response. Cancer Res. 2002. 62: 1884-1889.
23. Kanzler, H., Barrat, F. J., Hessel, E. M. and Coffman, R. L., Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat. Med. 2007. 13: 552-559.
24. Reis e Sousa, C., Toll-like receptors and dendritic cells: For whom the bug tolls. Semin. Immunol. 2004. 16: 27-34.
25. Iwasaki, A. and Medzhitov, R., Toll-like receptor control of the adaptive immune responses. Nat. Immunol. 2004. 5: 987-995.
26. Schulz, O., Diebold, S. S., Chen, M., Naslund, T. I., Nolte, M. A., Alexopoulou, L., Azuma, Y. T. et al., Toll-like receptor 3 promotes cross-priming to virus-infected cells. Nature 2005. 433: 887-892.
27. Iyoda, T., Shimoyama, S., Liu, K., Omatsu, Y., Akiyama, Y., Maeda, Y., Takahara, K. et al., The CD81 dendritic cell subset selectively endocytoses dying cells in culture and in vivo. J. Exp. Med. 2002. 195: 1289-1302.
28. Schulz, O. and Reis e Sousa, C., Cross-presentation of cell-associated antigens by CD8alpha1 dendritic cells is attributable to their ability to internalize dead cells. Immunology 2002. 107: 183-189.
29. Chen, X., Doffek, K., Sugg, S. L. and Shilyansky, J., Phosphatidylserine regulates the maturation of human dendritic cells. J. Immunol. 2004. 173: 2985-2994.
30. Otsuka, M., Goto, K., Tsuchiya, S. and Aramaki, Y., Phosphatidylserinespecific receptor contributes to TGF-beta production in macrophages through a MAP kinase, ERK. Biol. Pharm. Bull. 2005. 28: 1707-1710.
31. Shi, D., Fu, M., Fan, P., Li, W., Chen, X., Li, C., Qi, X. et al., Artificial phosphatidylserine liposome mimics apoptotic cells in inhibiting maturation and immunostimulatory function of murine myeloid dendritic cells in response to 1-chloro-2,4-dinitrobenze in vitro. Arch. Dermatol. Res. 2007. 299: 327-336.
32. Aliberti, J., Hieny, S., Reis e Sousa, C., Serhan, C. N. and Sher, A., Lipoxin-mediated inhibition of IL-12 production by DCs: A mechanism for regulation of microbial immunity. Nat. Immunol. 2002. 3: 76-82.
33. Gaipl, U. S., Beyer, T. D., Baumann, I., Voll, R. E., Stach, C. M., Heyder, P., Kalden, J. R. et al., Exposure of anionic phospholipids serves as anti-inflammatory and immunosuppressive signal - implications for antiphospholipid syndrome and systemic lupus erythematosus. Immunobiology 2003. 207: 73-81.
34. Eken, C., Gasser, O., Zenhaeusern, G., Oehri, I., Hess, C. and Schifferli, J. A., Polymorphonuclear neutrophil-derived ectosomes interfere with the maturation of monocyte-derived dendritic cells. J. Immunol. 2008. 180: 817-824.
35. Lau, C. M., Broughton, C., Tabor, A. S., Akira, S., Flavell, R. A., Mamula, M. J., Christensen, S. R., et al., RNA-associated autoantigens activate B cells by combined B cell antigen receptor/ Toll-like receptor 7 engagement. J. Exp. Med. 2005. 202: 1171-1177.
36. Leadbetter, E. A., Rifkin, I. R., Hohlbaum, A. M., Beaudette, B. C., Shlomchik, M. J. and Marshak-Rothstein, A., Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature 2002. 416: 603-607.
37. Tsan, M. F. and Gao, B., Endogenous ligands of Toll-like receptors. J. Leukoc. Biol. 2004. 76: 514-519.
38. Chen, C. J., Kono, H., Golenbock, D., Reed, G., Akira, S. and Rock, K. L., Identification of a key pathway required for the sterile inflammatory response triggered by dying cells. Nat. Med. 2007. 13: 851-856.
39. Casares, N., Pequignot, M. O., Tesniere, A., Ghiringhelli, F., Roux, S., Chaput, N., Schmitt, E. et al., Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J. Exp. Med. 2005. 202: 1691-1701.
40. Obeid, M., Tesniere, A., Ghiringhelli, F., Fimia, G.M., Apetoh, L., Perfettini, J. L., Castedo, M. et al., Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat. Med. 2007. 13: 54-61.
41. Apetoh, L., Ghiringhelli, F., Tesniere, A., Obeid, M., Ortiz, C., Criollo, A., Mignot, G. et al., Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat. Med. 2007. 13: 1050-1059.
42. Park, J. S., Svetkauskaite, D., He, Q., Kim, J. Y., Strassheim, D., Ishizaka, A. and Abraham, E., Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J. Biol. Chem. 2004. 279: 7370-7377.
43. McMahon, B. and Godson, C., Lipoxins: Endogenous regulators of inflammation. Am. J. Physiol. Renal Physiol. 2004. 286: F189-F201.
44. Aliberti, J., Serhan, C. and Sher, A., Parasite-induced lipoxin A4 is an endogenous regulator of IL-12 production and immunopathology in Toxoplasma gondii infection. J. Exp. Med. 2002. 196: 1253-1262.
45. Machado, F. S., Johndrow, J. E., Esper, L., Dias, A., Bafica, A., Serhan, C. N. and Aliberti, J., Anti-inflammatory actions of lipoxin A4 and aspirin-triggered lipoxin are SOCS-2 dependent. Nat. Med. 2006. 12: 330-334.
46. Arita, M., Bianchini, F., Aliberti, J., Sher, A., Chiang, N., Hong, S., Yang, R. et al., Stereochemical assignment, antiinflammatory properties, and receptor for the omega-3 lipid mediator resolvin E1. J. Exp. Med. 2005. 201: 713-722.
47. Arita, M., Ohira, T., Sun, Y. P., Elangovan, S., Chiang, N. and Serhan, C. N., Resolvin E1 selectively interacts with leukotriene B4 receptor BLT1 and ChemR23 to regulate inflammation. J. Immunol. 2007. 178: 3912-3917.
48. Gardai, S. J., Bratton, D. L., Ogden, C. A. and Henson, P. M., Recognition ligands on apoptotic cells: A perspective. J. Leukoc. Biol. 2006. 79: 896-903.
49. Lauber, K., Blumenthal, S. G., Waibel, M. and Wesselborg, S., Clearance of apoptotic cells: Getting rid of the corpses. Mol. Cell 2004. 14: 277-287.
50. Hoffmann, P. R., deCathelineau, A. M., Ogden, C. A., Leverrier, Y., Bratton, D. L., Daleke, D. L., Ridley, A. J. et al., Phosphatidylserine (PS) induces PS receptor-mediated macropinocytosis and promotes clearance of apoptotic cells. J. Cell. Biol. 2001. 155: 649-659.
51. Bondanza, A., Zimmermann, V. S., Rovere-Querini P, Turnay, J., Dumitriu, I. E., Stach, C. M., Voll, R. E. et al., Inhibition of phosphatidylserine recognition heightens the immunogenicity of irradiated lymphoma cells in vivo. J. Exp. Med. 2004. 200: 1157-1165.
52. Hoffmann, P. R., Kench, J. A., Vondracek, A., Kruk, E., Daleke, D. L., Jordan, M., Marrack, P. et al., Interaction between phosphatidylserine and the phosphatidylserine receptor inhibits immune responses in vivo. J. Immunol. 2005. 174: 1393-1404.
53. Fadok, V. A., Bratton, D. L., Konowal, A., Freed, P. W., Westcott, J. Y. and Henson, P. M. Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-beta, PGE2, and PAF. J. Clin. Invest. 1998. 101: 890-898.
54. Huynh, M. L., Fadok, V. A. and Henson, P. M., Phosphatidylserine-dependent ingestion of apoptotic cells promotes TGF-beta1 secretion and the resolution of inflammation. J. Clin. Invest. 2002. 109: 41-50.
55. Stuart, L. M., Lucas, M., Simpson, C., Lamb, J., Savill, J and Lacy-Hulbert, A., Inhibitory effects of apoptotic cell ingestion upon endotoxin-driven myeloid dendritic cell maturation. J. Immunol. 2002. 168: 1627-1635.
56. Schnurr, M., Scholz, C., Rothenfusser, S., Galambos, P., Dauer, M., Robe, J., Endres, S. and Eigler, A., Apoptotic pancreatic tumor cells are superior to cell lysates in promoting cross-priming of cytotoxic T cells and activate NK and gammadelta T cells. Cancer Res. 2002. 62: 2347-2352.
57. Inaba, K., Inaba, M., Romani, N., Aya, H., Deguchi, M., Ikehara, S., Muramatsu, S. and Steinman, R. M. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J. Exp. Med. 1992. 176: 1693-1702.